• Skip to primary navigation
  • Skip to main content
SRI InternationalSRI mobile logo

SRI International

SRI International - American Nonprofit Research Institute

  • About
    • Blog
    • Press room
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Show Search
Hide Search
Biomedical sciences publications November 1, 2009 Journal Article

Bright Lights, Clearly Visible in the Healthcare R&D Tunnel, Could Burn Out for Lack of Funds

SRI International November 1, 2009

Citation

Copy to clipboard


Moos, W. H., Rurka, J. E. and Miller, S. M. (2009), Bright lights, clearly visible in the healthcare R&D tunnel, could burn out for lack of funds. Drug Dev. Res., 70: 457–460. doi: 10.1002/ddr.20354

Abstract

Bright lights have never been more visible in healthcare R&D, each heralding innovative approaches to disease diagnosis, treatment, or prevention. Unfortunately, this promise of continued healthcare innovation is increasingly threatened by inadequate funding of R&D at many levels: in academic and nonprofit organizations, in small business ventures, and even in large pharmaceutical companies. If we are to continue transforming the practice of medicine, we must ensure that R&D funding levels are made sufficient to leverage recent scientific advances into important new medicines. Thanks to legions of dedicated researchers over the last century, we are making significant progress against major killers. The next generation of drugs and biologics could delay the onset of neurodegenerative diseases like Alzheimer’s for long enough to be considered a “cure.” Current experience with pandemic swine flu has acquainted the population-at-large with an idea of the magnitude of potential risks created by a “bad bugs, no drugs” scenario. Innovative biomedical R&D has been so successful for so long that many of us who live in the developed world now consider good health to be an entitlement. We simply cannot afford to miss the enormous opportunities now coming into focus, which promise to relieve suffering, reduce morbidity, and eliminate so many needless deaths. Several focal points are recommended as the basis around which we might begin to address these needs at the NIH and FDA, along with small businesses and big pharma.

↓ View online

Share this

Facebooktwitterlinkedinmail

Biomedical sciences publications, Publication Journal Article

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs
Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Blog

Institute

Leadership

Press room

Media inquiries

Compliance

Privacy policy

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter

日本支社

SRI International

  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International